Noramco, a global active pharmaceutical ingredients (API) manufacturer specializing in controlled substances, has acquired Cambrex Drug Product Business Unit previously known as Halo Pharmaceuticals. The acquisition will provide API customers of Noramco, and its subsidiary Purisys, additional service options such as drug product formulation development, clinical and commercial drug product manufacturing, and packaging from facilities in Mirabel, Québec and Whippany, NJ. Noramco is returning to the Halo Pharmaceutical brand as part of this acquisition.

“This acquisition allows Noramco to provide our customers with more sourcing options beyond APIs, said Noramco CEO Lee Karras. “With these additional capabilities, Noramco/Purisys customers can develop drug product formulations for their APIs for both clinical and commercial purposes. Having previously operated the Halo Pharmaceuticals business, I have a direct appreciation of the capabilities of both sites and look forward to working with existing and future customers while welcoming the almost 400 new employees to the Noramco group of companies.”